CD34 immunohistochemistry of bone marrow biopsies: Prognostic significance in primary myelodysplastic syndromes

Davide Soligo, D Nosella(Ospedale San Carlo), Attilio Orazi(Texas Tech University), E Pozzoli(University of Milan), C. Annaloro(University of Milan), Rossella Calori(IRCCS Policlinico San Donato), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Alessandro Oriani(Istituti di Ricovero e Cura a Carattere Scientifico)

American Journal of Hematology

May 1, 1994

10.1002/ajh.2830460103

Cited by 50

Related Papers

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

|Blood|2022|2.8k

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

|Journal of Clinical Oncology|2012|682

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

|Blood|2009|433

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396